RNA Outsourcing Resources

  1. 5 Key Considerations For Companies Outsourcing Process Development 6/9/2025

    Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

  2. Screening T7 Polymerases To Optimize xRNA Yield And Quality 10/31/2025

    Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

  3. Improving Pre-Clinical Study Efficiency With mRNA-LNP Technology 11/20/2024

    Uncover how Repair Biotechnologies, in collaboration with Vernal Biosciences, helped to pave the way for the next generation of breakthrough treatments for cholesterol and aging-related diseases.

  4. The Current And Future Value Of mRNA Vaccines And Therapeutics 2/4/2026

    Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.

  5. Advancing Cell And Gene Therapy Clinical Development In 2023 7/19/2023

    Examine considerations on bringing together the CMC and clinical teams early in the development process, promoting transparency and communication with regulators, and increasing patient access and diversity in clinical trials.

  6. Exploring The Spatial Distribution Of mRNA-Lipid Nanoparticles Using MALDI MSI 4/23/2025

    Learn how leveraging high-resolution MALDI-MSI can advance the development of lipid nanoparticle-based therapies, uncovering spatial biodistribution, pharmacokinetics, and organ-specific variability.

  7. Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions 4/21/2021

    Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.

  8. Expression Analysis Of CTLA-4, PD-1, And PD-L1 4/23/2025

    Advance personalized immunotherapy in NSCLC by leveraging qPCR-based analysis of CTLA-4, PD-1, and PD-L1 expression to identify predictive biomarkers and guide more effective treatment strategies.

  9. mRNA Manufacturing And Formulation 11/15/2022

    From fermentation to formulation, mRNA manufacturing requires a toolbox of technologies, services, and expertise. Explore our portfolio of solutions for making, purifying, and formulating mRNA.

  10. Writing Effective Clinical Regulatory Documents For Therapy Trials 7/11/2025

    Clinical medical writing for gene therapy regulatory documents is a demanding, detail-oriented task that diverges significantly from medical writing for more traditional therapies.